Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals, Inc. (NRXP) received a positive determination from the Nasdaq Hearings Panel for its listing transfer to The Nasdaq Capital Market. The company must demonstrate compliance with a $35 million market value of listed securities and a $1.00 minimum bid price by April 16, 2024. NRx believes it has met the market value requirement and is working to meet the bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:51 am

NRx Pharmaceuticals has been granted FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for NRX-101, aimed at treating complicated urinary tract infections and pyelonephritis. These designations could expedite the development and review process for NRX-101, potentially bringing it to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 11:52 am

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will present a keynote address on ketamine's efficacy and risks for treating suicidal depression at the Sachs Neuroscience Innovation Forum. The company plans to file a New Drug Application for ketamine in 2024 in the US and EU. NRx has shown ketamine's superiority to placebo and non-inferiority to electroshock therapy in trials. They are developing a new formulation with Nephron Pharmaceuticals and a REMS program. NRx has created HOPE Therapeutics, Inc. to advance ketamine's development and will award rights to shareholders and new investors. NRx is also developing NRX-101 for suicidal bipolar depression and chronic pain, in partnership with Alvogen Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:45 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has announced its plans to comply with Nasdaq's minimum bid price and Market Value of Listed Securities (MVLS) requirements. The company previously received two deficiency notices from Nasdaq for not maintaining a minimum $1 bid price and an MVLS of $50 million. NRx Pharmaceuticals intends to present a full compliance plan to Nasdaq by January 4, 2024, which will be based on achieving clinical milestones.

Portfolio Pulse from Charles Gross

January 02, 2024 | 11:55 am

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) saw a substantial increase of 59.9%, while Clene (CLNN), Acutus Medical (AFIB), Avinger (AVGR), Blue Water Biotech (BWV), and Biora Therapeutics (BIOR) also gained. Conversely, Biophytis (BPTS), Guardant Health (GH), Syros Pharmaceuticals (SYRS), Alzamend Neuro (ALZN), Ensysce Biosciences (ENSC), and NRX Pharmaceuticals (NRXP) faced declines, with Biophytis leading the losses.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 9:31 pm

NRx Pharmaceuticals has entered into an agreement with Columbia University for the rights to data from a trial on the effectiveness of Ketamine in treating acute suicidality in depression. The trial showed Ketamine to be highly effective, and NRx plans to use this data to support a New Drug Application to the FDA in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:19 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biomerica, Cingulate, Arcutis Biotherapeutics, Panbela Therapeutics, NRX Pharmaceuticals, and Alaunos Therapeutics saw their shares rise by 54.5%, 33.33%, 31.14%, 30.54%, 30.08%, and 29.89% respectively. Conversely, Minerva Surgical, Checkpoint Therapeutics, Structure Therapeutics, Lantheus Holdings, Ainos, and Blue Water Biotech faced declines of 52.5%, 50.31%, 45.24%, 18.8%, 18.08%, and 16.08% respectively.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:07 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Jin Medical International (ZJYL) saw a substantial increase of 72.5%, while NRX Pharmaceuticals (NRXP) led the losers with a 12.1% decrease. Other notable gainers include Panbela Therapeutics (PBLA), IN8bio (INAB), Reviva Pharmaceuticals (RVPH), CNS Pharma (CNSP), and Nexalin Technology (NXL). On the losing side, bluebird bio (BLUE), Senti Biosciences (SNTI), Motus GI Holdings (MOTS), Zura Bio (ZURA), and BioAtla (BCAB) also saw declines.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:31 pm

NRx Pharmaceuticals' stock price has increased following the announcement that the FDA has cleared its Investigational New Drug (IND) application for NRX-101.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:44 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Biomerica (BMRA) saw a 71.7% increase, while Arcutis Biotherapeutics (ARQT) rose by 41.8%. Alaunos Therapeutics (TCRT), Akili (AKLI), Applied DNA Sciences (APDN), and NRX Pharmaceuticals (NRXP) also gained. Conversely, Minerva Surgical (UTRS) dropped by 53.9%, Checkpoint Therapeutics (CKPT) by 49.7%, Structure Therapeutics (GPCR) by 40.96%, Blue Water Biotech (BWV) by 16.88%, Lantheus Holdings (LNTH) by 15.84%, and Lantern Pharma (LTRN) by 13.01%.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 1:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.